APOB and familial hypercholesterolemia: In 2009, three novel drugs entered clinical evaluation, two of which, ALN-TTR01 and TKM-ApoB were SNALP-based delivery systems targeting hepatocytes and formulated with anti- Transthyretin (TTR) and anti-ApoB siRNAs in ATTR and hypercholesterolemia patients, respectively [9].